Ribo Life Science Secures EMA Approval to Launch Phase 2b MRCT of siRNA Candidate Vortosiran for AF-Related Stroke Prevention

Bulletin Express

Jul 28

On 28 July 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) disclosed that the European Medicines Agency has authorised the initiation of ORBIT-XI-AF, a Phase 2b multi-regional clinical trial evaluating vortosiran (RBD4059) for stroke prevention in patients with atrial fibrillation (SPAF).

Vortosiran is described as the world’s first and most advanced small interfering RNA therapy targeting coagulation Factor XI. Developed via the company’s proprietary RiboGalSTAR™ liver-targeting platform, the GalNAc-conjugated siRNA selectively suppresses FXI synthesis, inhibiting the intrinsic coagulation pathway to deliver antithrombotic activity.

Human genetic data cited in the announcement indicate that naturally reduced FXI levels are linked to lower thrombotic risk without a corresponding rise in spontaneous bleeding, positioning FXI inhibition as a potentially safer anticoagulation strategy relative to current therapies.

The EMA’s green light marks a pivotal milestone in Ribo Life Science’s global development programme for next-generation anticoagulants, enabling advancement of vortosiran into the next stage of clinical evaluation.

The company cautions that vortosiran may not ultimately achieve successful development or commercialisation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1119391095"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1119391095\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1119391095?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119391095","market":"us","top_or_hot":-1,"title":"Ribo Life Science Secures EMA Approval to Launch Phase 2b MRCT of siRNA Candidate Vortosiran for AF-Related Stroke Prevention","media":"Bulletin Express","content":"<p>On 28 July 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) disclosed that the European Medicines Agency has authorised the initiation of ORBIT-XI-AF, a Phase 2b multi-regional clinical trial evaluating vortosiran (RBD4059) for stroke prevention in patients with atrial fibrillation (SPAF).</p>\n<p>Vortosiran is described as the world’s first and most advanced small interfering RNA therapy targeting coagulation Factor XI. Developed via the company’s proprietary RiboGalSTAR™ liver-targeting platform, the GalNAc-conjugated siRNA selectively suppresses FXI synthesis, inhibiting the intrinsic coagulation pathway to deliver antithrombotic activity.</p>\n<p>Human genetic data cited in the announcement indicate that naturally reduced FXI levels are linked to lower thrombotic risk without a corresponding rise in spontaneous bleeding, positioning FXI inhibition as a potentially safer anticoagulation strategy relative to current therapies.</p>\n<p>The EMA’s green light marks a pivotal milestone in Ribo Life Science’s global development programme for next-generation anticoagulants, enabling advancement of vortosiran into the next stage of clinical evaluation.</p>\n<p>The company cautions that vortosiran may not ultimately achieve successful development or commercialisation.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ribo Life Science Secures EMA Approval to Launch Phase 2b MRCT of siRNA Candidate Vortosiran for AF-Related Stroke Prevention</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRibo Life Science Secures EMA Approval to Launch Phase 2b MRCT of siRNA Candidate Vortosiran for AF-Related Stroke Prevention\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-28 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 28 July 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) disclosed that the European Medicines Agency has authorised the initiation of ORBIT-XI-AF, a Phase 2b multi-regional clinical trial evaluating vortosiran (RBD4059) for stroke prevention in patients with atrial fibrillation (SPAF).</p>\n<p>Vortosiran is described as the world’s first and most advanced small interfering RNA therapy targeting coagulation Factor XI. Developed via the company’s proprietary RiboGalSTAR™ liver-targeting platform, the GalNAc-conjugated siRNA selectively suppresses FXI synthesis, inhibiting the intrinsic coagulation pathway to deliver antithrombotic activity.</p>\n<p>Human genetic data cited in the announcement indicate that naturally reduced FXI levels are linked to lower thrombotic risk without a corresponding rise in spontaneous bleeding, positioning FXI inhibition as a potentially safer anticoagulation strategy relative to current therapies.</p>\n<p>The EMA’s green light marks a pivotal milestone in Ribo Life Science’s global development programme for next-generation anticoagulants, enabling advancement of vortosiran into the next stage of clinical evaluation.</p>\n<p>The company cautions that vortosiran may not ultimately achieve successful development or commercialisation.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06938","symbol_name":"瑞博生物-B","start_time":0,"source_url":"","article_id":"1119391095","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119391095","pubTimestamp":1785240379,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 28 July 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) disclosed that the European Medicines Agency has authorised the initiation of ORBIT-XI-AF, a Phase 2b multi-regional clinical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06938":"瑞博生物-B"},"translate_title":"Ribo Life Science 获得 EMA 批准，启动 siRNA 候选药物 Vortosiran 的 2b 期 MRCT，用于预防房颤相关中风","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1},"content_text":"On 28 July 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) disclosed that the European Medicines Agency has authorised the initiation of ORBIT-XI-AF, a Phase 2b multi-regional clinical trial evaluating vortosiran (RBD4059) for stroke prevention in patients with atrial fibrillation (SPAF).\nVortosiran is described as the world’s first and most advanced small interfering RNA therapy targeting coagulation Factor XI. Developed via the company’s proprietary RiboGalSTAR™ liver-targeting platform, the GalNAc-conjugated siRNA selectively suppresses FXI synthesis, inhibiting the intrinsic coagulation pathway to deliver antithrombotic activity.\nHuman genetic data cited in the announcement indicate that naturally reduced FXI levels are linked to lower thrombotic risk without a corresponding rise in spontaneous bleeding, positioning FXI inhibition as a potentially safer anticoagulation strategy relative to current therapies.\nThe EMA’s green light marks a pivotal milestone in Ribo Life Science’s global development programme for next-generation anticoagulants, enabling advancement of vortosiran into the next stage of clinical evaluation.\nThe company cautions that vortosiran may not ultimately achieve successful development or commercialisation.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}